0001562180-22-000587.txt : 20220124
0001562180-22-000587.hdr.sgml : 20220124
20220124060139
ACCESSION NUMBER: 0001562180-22-000587
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220119
FILED AS OF DATE: 20220124
DATE AS OF CHANGE: 20220124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Clark George C.
CENTRAL INDEX KEY: 0001878290
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38080
FILM NUMBER: 22547354
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Biohaven Pharmaceutical Holding Co Ltd.
CENTRAL INDEX KEY: 0001689813
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
BUSINESS PHONE: 203-404-0410
MAIL ADDRESS:
STREET 1: 215 CHURCH STREET
CITY: NEW HAVEN
STATE: CT
ZIP: 06510
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2022-01-19
false
0001689813
Biohaven Pharmaceutical Holding Co Ltd.
BHVN
0001878290
Clark George C.
C/O BIOHAVEN PHARMACEUTICALS, INC.
215 CHURCH STREET
NEW HAVEN
CT
06510
false
true
false
false
VP, Chief Accounting Officer
Common Shares
2022-01-19
4
M
false
3750.00
53.76
A
13470.00
D
Common Shares
2022-01-19
4
M
false
1920.00
32.42
A
15390.00
D
Common Shares
2022-01-19
4
S
false
3196.00
114.9293
D
12194.00
D
Common Shares
2022-01-19
4
S
false
2159.00
116.0189
D
10035.00
D
Common Shares
2022-01-19
4
S
false
500.00
118.048
D
9535.00
D
Common Shares
2022-01-19
4
S
false
3520.00
119.3694
D
6015.00
D
Employee Stock Option (right to buy)
53.76
2022-01-19
4
M
false
3750.00
0.00
D
2029-12-05
Common Shares
3750.00
4500.00
D
Employee Stock Option (right to buy)
32.42
2022-01-19
4
M
false
1920.00
0.00
D
2028-11-20
Common Shares
1920.00
2875.00
D
These exercises and sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.30 - $115.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.39 - $116.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 - $118.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.84 - $119.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The shares underlying this option vest in four equal installments on December 5, 2019, 2020, 2021 and 2022, subject to the reporting person's continued service with the issuer at each vesting date.
The shares underlying this option vest in four equal installments on November 20, 2019, 2020, 2021 and 2022, subject to the reporting person's continued service with the issuer at each vesting date.
/s/ George Clark
2022-01-24